Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004583 · ClinicalTrials.gov registry record · Phase 3
A Phase III Study Comparing Two Different Anti-HIV Drug Combinations in HIV-Positive Patients Without Previous Anti-HIV Drug Therapy
A Phase 3 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 660
- Enrollment target
NCT00004583: Completed Phase 3 study, sponsored by Abbott.
NCT00004583 is a Phase 3 study that has completed, run by Abbott. The registered enrollment target is 660 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (15% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004583, a Phase 3 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 660 participants
- Enrollment target
Study Summary
The purpose of this study is to see how safe a new protease inhibitor (PI) is and how well it fights HIV infection. A PI is a drug that stops HIV from using healthy cells to make more virus. This study will compare the new PI combination of ABT-378 plus ritonavir (RTV) with another PI, nelfinavir (NFV). Earlier studies suggest ABT-378/RTV will be just as good as and perhaps better than NFV at fighting HIV infection.
Interventions
- DRUG Lamivudine
- DRUG Stavudine
- DRUG Nelfinavir mesylate
- DRUG Lopinavir/Ritonavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 660 participants |
| Start Date | 1999-03 |
| Phase | Phase 3 |
What the finished NCT00004583 record still lists
NCT00004583 is an interventional study that assigns participants to a tested intervention. The registered 660 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (15% lower).
The record links to 0 conditions, and to 4 interventions - of which Lamivudine is the first listed.
NCT00004583 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004583 about?
NCT00004583 is a clinical study titled "A Phase III Study Comparing Two Different Anti-HIV Drug Combinations in HIV-Positive Patients Without Previous Anti-HIV Drug Therapy". The purpose of this study is to see how safe a new protease inhibitor (PI) is and how well it fights HIV infection. A PI is a drug that stops HIV from using healthy cells to make more virus. This study will compare the new PI combination of ABT-378 plus ritonavir (RTV) with another PI, nelfinavir (N...
What is the current status of trial NCT00004583?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 660 participants. The study started on 1999-03.
What interventions are being tested in trial NCT00004583?
The interventions under investigation include: Lamivudine (DRUG), Stavudine (DRUG), Nelfinavir mesylate (DRUG), Lopinavir/Ritonavir (DRUG).
Who is sponsoring clinical trial NCT00004583?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00004583's enrollment target sits among peer trials
660 556th of 2000 higher than 1,440 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01185132 · 660 participants · Phase 3
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
- NCT03346694 · 660 participants · NA
Reducing Surgical Site Infection Rates Using an Alternative Sternal Dressing
- NCT05407636 · 660 participants · Phase 3
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
- NCT05470205 · 660 participants · Phase 3
Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension; Renewal
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia